May 24, 2024 11:24 AM EDTUpdated 01:50 PM
R&D

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers

ENDPOINTS

Read on for news about Im­muno­core, Ar­cus, CG On­col­o­gy, Gen­mab, Mer­ck and GSK:

Merus stock spikes on da­ta in head and neck squa­mous cell car­ci­no­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times